← All trials
NCT04264897
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2020
- Primary completion
- Apr 30, 2024
- Completion date
- Apr 30, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 148
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Oklahoma Medical Research FoundationLead sponsor
- University of IllinoisCollaborator
- University of IllinoisOverall official - principal investigator
- University of OklahomaCollaborator
- National Institute on Aging (NIA)Collaborator
- Oklahoma Medical Research FoundationOverall official - principal investigator
- Oklahoma Medical Research FoundationReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.